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Abstract  
 
Introduction: Advanced melanoma with a BRAF V600 mutation responds to 
treatment with BRAF inhibitors such as vemurafenib, with great improvement in 
tumour response and patient survival. Despite early and often dramatic 
responses, resistance to vemurafenib develops. Concurrent inhibition of a 
downstream protein, MEK, also involved in the MAPK oncogenic signalling 
pathway, defers development of resistance. The MEK inhibitor cobimetinib has 
been successfully and safely combined with vemurafenib, further improving 
response rate and survival when compared to vemurafenib monotherapy. 
 
Areas covered: This article covers the mechanism of action of both vemurafenib 
and cobimetinib, in addition to describing results from the key Phase I and 
Phase III studies which led to registration of the combination in the US and 
Europe as a therapeutic option for advanced BRAF mutant melanoma. The safety 
profile of these agents is also discussed in detail, including similarities with and 
differences from the competitor compounds dabrafenib and trametinib. 
Expert opinion: Vemurafenib in combination with cobimetinib provides an 
 alternative BRAF/MEK blockade. The combination is tolerable, safe and effective 
and results in fewer skin toxicities than vemurafenib monotherapy. 
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1.1 Introduction 
 
Malignant melanoma is the most aggressive form of cutaneous malignancy with 
approximately 132,000 new cases diagnosed globally each year. In the UK, it is 
the 5th commonest cancer accounting for nearly 13,000 cases and over 2000 
deaths a year.1 The incidence of melanoma is rising steadily with a doubling of 
the number of cases every decade, a rate of increase more rapid than any other 
form of solid cancer. Historically, advanced cutaneous melanoma has been 
associated with an extremely poor outlook; until recently the median survival 
of such patients was in the order of 6 to 9 months, with only 10-15% of patients 
alive at 3 years.2 
 
 
Approximately 50% of cutaneous melanomas harbour a BRAF V600 mutation 
resulting in constitutive BRAF activation, integral to oncogenic signalling via the 
mitogen activated protein kinase (MAPK) pathway.3, 4 This discovery has led to 
the development of several molecular targeted therapies in recent years. The 
BRAF inhibitors vemurafenib and dabrafenib demonstrated a significant 
improvement in progression-free and overall survival as compared with 
standard chemotherapy alone in patients with advanced BRAF V600E mutated 
melanoma, leading to their approval.5, 6 
  
Despite the impressive initial responses demonstrated with BRAF inhibition in 
advanced melanoma, these are short-lived for the vast majority of patients with 
most developing resistance to therapy within 6 to 9 months.5, 6 Multiple 
mechanisms of acquired resistance are described; amongst these reactivation of 
the MAPK signalling pathway accounts for acquired resistance in the large 
majority of patients.7 MEK is a protein downstream of BRAF and one such mode 
of MAPK reactivation. Accordingly, large-scale clinical trials have demonstrated 
combination BRAF/MEK inhibitor therapy to have superior clinical efficacy than 
BRAF inhibition alone with an improvement in progression-free survival and 
overall survival in patients with BRAF-mutated melanoma.8-10 This article 
focuses on the combination of vemurafenib with cobimetinib. 
 
 
1.2 Overview of the market 
 
In a renewed era of cancer immunotherapy, the FDA approval of novel 
immunomodulatory antibodies targeting T cell immune checkpoint molecules 
has led to a change in the management of BRAF-mutated melanoma with anti-
CTLA-4 and anti-PD-1 therapy incorporated into various clinical guidelines. The 
recommendation from the European Society for Medical Oncology (ESMO) for 
the treatment of BRAF-mutated melanoma comprises first-line anti-PD-1 
treatment or combined BRAF/MEK inhibitor therapy.11 In the United States, 
National Comprehensive Cancer Network (NCCN) guidelines recommend using 
any of the following regimens in the first-line setting for patients with BRAF-
mutated melanoma: combined BRAF/MEK inhibition, single agent BRAF 
 inhibition, single agent anti-PD-1 therapy or combined anti-PD-1 and anti-CTLA-
4 therapy. 
 
 
 
In addition to clinical concerns regarding drug resistance, toxicity and 
tolerability of currently available molecular targeted drugs and immune 
checkpoint antibodies, well-defined treatment algorithms regarding the optimal 
sequence and timing of immunotherapy and molecular targeted therapy in 
 
BRAF-mutated melanoma remain a significant unmet clinical need in the 
management of metastatic melanoma.12 In patients with BRAF-mutated 
melanoma, in the context of symptomatic, large volume, rapidly progressive 
disease most clinicians favour use of targeted molecular therapy in the first 
instance where the priority is to achieve a rapid response. On the contrary, 
checkpoint blockade may be adopted first-line in patients with more indolent 
disease, reserving molecular targeted agents as salvage therapy at the time 
of disease progression. 
 
 
 
Two different BRAF/MEK inhibitor combinations are currently in use: 
dabrafenib/trametinib and vemurafenib/cobimetinib. Encorafenib plus 
Binimetinib is currently being tested in a phase III trial and data is awaited 
(NCT01909453). Several second-generation immune checkpoint modulators 
are being tested in clinical trials including anti-LAG-3, anti-4-1BB and anti-GITR 
therapies reflecting the significant interest in cancer immunotherapy following 
the recent clinical successes of various anti-PD-1 therapies.13 
 
 
2.1 Introduction to the compounds 
 Vemurafenib and cobimetinib inhibit BRAF and MEK proteins, respectively, 
within the MAPK pathway. This is the key growth signalling pathway in BRAF 
V600-mutated melanoma cells and is represented in Figure 1. 
 
 
 
Vemurafenib is an oral tyrosine kinase inhibitor administered twice a day at a 
dose of 960mg (each tablet contains 240mg), continuously. Cobimetinib is an 
oral tyrosine kinase inhibitor targeting the MEK protein. It is administered at a 
dose of 60mg (each tablet contains 20mg) daily, for three weeks out of four. 
 
 
 
Melanoma cells eventually develop resistance to BRAF inhibitor monotherapy 
via one of several mechanisms, for example by reactivation of the MAPK 
pathway through MEK signalling7, 14, CRAF upregulation15 and development of 
NRAS mutations16, 17, amongst others. Combined blockade of BRAF and MEK 
proteins defers development of resistance, allowing prolonged MAPK inhibition 
and therefore more durable tumour control. Concurrent blockade not only 
defers resistance, it also alters the side effect profile of both agents. 
 
 
 
2.2 Chemistry 
 
Vemurafenib has the chemical name propane-1-sulfonic acid [3-[5-(4-
chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4- difluoro-
phenyl]-amide and the molecular formula C23H18ClF2N3O3S.18 
 
Cobimetinib fumarate has the chemical name chemical name (S)-[3,4-difluoro-
2-(2-fluoro-4-292 iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-
yl)azetidin-1-yl]methanone hemifumarate and the molecular formula 
C46H46F6I2N6O8 (2 C21H21F3IN3O2 
. C4H4O4).19 
 
 
 
2.3 Pharmacodynamics 
 
Vemurafenib targets the mutant BRAF protein, inhibiting downstream protein 
phosphorylation of MEK. Ultimately this induces cell cycle arrest and apoptosis 
and thereby inhibits cellular proliferation and unregulated tumour growth. 
Vemurafenib was specifically engineered to provide greater inhibition of the 
mutant BRAF protein over the wild-type BRAF protein.20, 21 This enables 
higher drug concentration exposure, without serious side effects imposed upon 
BRAF wild-type tissues.22 
 
 
Cobimetinib binds to active, phosphorylated MEK 1/2 proteins in a selective 
manner.23 In doing so it prevents downstream phosphorylation of ERK and 
resultant oncogenic signalling. The dependency of BRAF mutated tumours on 
MEK signalling makes this a particularly rational combination.24 
 
 
Inhibition of MEK concurrent with BRAF results in less hyperkeratotic skin 
toxicity, including reduced development of squamous cell carcinomas. This 
toxicity is due to a paradoxical increase in MAPK signalling induced by BRAF 
inhibition, with secondary lesions often demonstrating a mutation in RAS, 
especially HRAS.25 Mutant RAS-driven increased signalling may also precipitate 
the development of RAS-mutant tumours, such as colorectal and pancreatic 
cancer.26, 27 It is possible that MEK inhibition can mitigate but not completely 
abrogate this process.26 
  
2.4 Pharmacokinetics and metabolism 
 
The pharmacokinetics of vemurafenib and cobimetinib are summarised in Table 1. 
Vemurafenib is a moderate CYP1A2 inhibitor and can also induce CYP3A4, its main 
metabolic pathway. Prescribers need to be aware of potential increased side effects 
and decreased efficacy of concurrent medications metabolised by these pathways. 
Concurrent use of medications with strong CYP3A4 inhibitory properties should be 
avoided in conjunction with cobimetinib, or if essential, close monitoring for 
adverse events should be instituted. 
 
3.0 Clinical efficacy 
 
3.1 Phase I trial 
 
A phase 1b study in advanced BRAF mutated melanoma assessed the safety of 
combination vemurafenib/cobimetinib with dose escalation in patients that were 
either naïve to BRAF inhibition (n=63) or had previously progressed on 
vemurafenib (n=66).28 Efficacy of combination therapy was measured as a 
secondary end point. Ten dosing regimens were chosen and 2 were escalated: 
vemurafenib 720mg BD with cobimetinib 60mg, 21 days on ad 7 days off, and 
vemurafenib 960mg BD with cobimetininb 60mg BD, 21 days on and 7 days off. The 
overall response rate (ORR) was 15% in patients who had previously received 
vemurafenib and 87% in BRAF inhibitor naïve patients, with a complete response 
(CR) rate of 10% and median progression free survival (PFS) of 13.7 months (95% 
CI 10.1-17.5) in this latter group. This was notably longer than the median PFS with 
vemurafenib monotherapy, reported at less than 7 months 
 (95% CI 2.6-3.4).29, 30 After extended follow up, the median OS in BRAF inhibitor 
naïve patients was reported as 31.2 months, with an OS of 37% at 3 years.31 
 
 
3.2 Phase III trial 
 
Larkin et al demonstrated the superior clinical efficacy of 
vemurafenib/cobimetinib in the Phase 3 coBRIM study in 2014.32 Four hundred 
and ninety five patients with unresectable locally advanced or metastatic BRAF 
V600 mutated melanoma were assigned to receive either 
vemurafenib/cobimetinib (combination) or vemurafenib/placebo (control) in 
the first line setting. The combination group had a significantly improved 
median PFS of 9.9months compared to 6.2 months, with HR of 0.51 for death or 
disease progression (95% CI 0.39-0.68, p<0.001). The rate of partial response 
(PR) or CR was 68% compared to 45% in the control group. Consistent with the 
phase 1 results, there was a non-significant increase in grade 3 or 4 adverse 
events in the combination group, including elevated creatine kinase and liver 
function tests, with no increased rate of discontinuation of treatment. 
Furthermore, there was a decreased incidence of squamous cell carcinoma (SCC) 
incidence in the combination group. 
 
 
 
Updated coBRIM results at 14.2 months’ follow-up confirmed the clinical 
benefit of combination treatment.33 The median PFS was 12.3 months in the 
combination group, compared to 7.2 months in the control group, HR 0.58 (95% 
CI 0.46-0.72). The ORR was 70% in the combination group versus 50%, with CR 
in 16% vs 11% in the control group. At 18.5 months follow up the median OS 
was 23.3 months in the combination group versus 17.4 months (HR, 0.70; 95% 
CI, 0.55-0.90; P = .005), and 2 year OS 48% versus 38%.34 Clinical benefit was 
seen consistently across mutation types, including BRAF V600E and V600K and 
presence of RAS or RTK mutations did not affect clinical outcomes.35 
 
 
In addition, health related quality of life was assessed with the EORTC QLQ-C30 
questionnaire and reported better scores in all functioning domains of the 
questionnaire in the combination group after baseline, but not all reached 
clinically meaningful (CM) criteria.36 The CM criteria were met for 
improvements in insomnia, fatigue, social functioning and pain but as predicted 
the combination group had worsening of diarrhoea. 
 
 
 
Post-marketing surveillance is yet to be reported for this combination, 
although a large safety study on vemurafenib monotherapy did not raise any 
new safety signals.37 
 
 
Table 2 summarises the efficacy results from the Phase I and III trials of 
vemurafenib/cobimetinib and dabrafenib/trametinib. 
 
 
3.3 Ongoing trials 
 
There are a number of other ongoing studies assessing BRAF and MEK 
inhibition with combination vemurafenib and cobimetinib, including a second 
Phase 3 study (NCT02427893) comparing this combination with 10 days of 
monotherapy of either drug prior to combination treatment. 
 The optimisation of dosing and sequencing is also being explored in a phase 2 
study comparing intermittent and continuous dosing (NCT 02583516). 
Intermittent vemurafenib was shown to increase drug tolerability without 
obviously limiting efficacy in a small case series.38 Therefore, intermittent 
dosing of vemurafenib in combination treatment may provide a similar benefit. 
Intermittent combination treatment was given safely to a patient with BRAF 
mutant melanoma who developed rapid progression of NRAS-mutant leukaemia 
on vemurafenib. He received a further 35 weeks of combination treatment with 
vemurafenib and cobimetinib. Response has been maintained at nearly twenty 
months, illustrating that there is potential for such an approach.39 
 
 
There is also an ongoing trial (NCT02537600 CONVERCE) to determine the 
intracranial efficacy of this combination in BRAF mutated metastatic melanoma 
patients with brain metastases. Another similar phase 2 study was unfortunately 
terminated early due to slow accrual (NCT02230306 coBRIM-B). 
 
 
 
Surgery continues to play an important role in Stage I to III melanoma as well as 
in selected cases of Stage IV disease. The potential role of combination targeted 
therapy in the treatment paradigm requires consideration, for example to 
optimize the surgical approach or convert from unresectable to resectable 
disease. Combination vemurafenib and cobimetinib is being assessed in the 
neoadjuvant setting with patients who have palpable lymph nodes (stage 
IIIB/IIIC) receiving 2 months of treatment prior to surgery and adjuvant 
combination treatment to a maximum of 12 months (NCT02036086). Another 
Phase 2 study is also assessing neoadjuvant combination therapy over 18 weeks 
 in stage IIIC/IV disease and also aims to identify predictive and prognostic 
biomarkers (NCT02303951). A phase III trial of dabrafenib and trametinib 
following surgery for patients with high risk BRAF V600 mutation positive 
melanoma (COMBI-AD) is ongoing and results are awaited (NCT01682083). 
Similarly, a phase III study of vemurafenib monotherapy given to patients with 
 
BRAF V600 mutant melanoma in the adjuvant setting has closed to accrual 
and outcomes are pending (NCT01667419). 
 
 
Whilst the combination of vemurafenib and cobimetinib has shown promising 
results, further research into maximising response rates and efficacy by adding 
other targeted treatments is important. The phase 2 study examining the benefit 
of additional bevacizumab was terminated due to toxicity and slow accrual 
(NCT01495988). However, there are active studies to assess the safety and 
efficacy of future combinations, including the addition of decitabine, which 
disrupts DNA methylation (NCT01876641) and may give benefit to BRAF 
inhibitor resistant melanoma patients. 
 
 
 
Finally, with the success of immunotherapy in melanoma treatment in the 
last decade it is important to investigate the impact of targeted therapies on 
the tumour immune microenvironment. 
 
 
 
A Phase 2 study (NCT01813214) will explore the effect of vemurafenib and 
cobimetinib on the immune response to melanoma, including T cell infiltration 
and the presence and expression of immune mediating proteins and genes. 
 There is also a Phase 1b study (NCT01656642) comparing vemurafenib alone or 
in combination with cobimetinib with the addition of an anti-PD-L1 drug 
(atezolizumab) in both cohorts in BRAF mutant metastatic melanoma. 
 
 
4. Safety and tolerability 
 
Trials of vemurafenib have established the common adverse events observed 
with this drug when used as monotherapy. These include rash (42%), fatigue 
(45%), arthralgia (58%), photosensitivity (41%), cutaneous squamous cell 
carcinoma (19%), nausea (40%) and raised liver function tests (36%).40 
 
 
Data regarding cobimetinib as a monotherapy in advanced melanoma is not 
published, however the MEK inhibitor trametinib was studied in a Phase III trial 
by Flaherty et al and the most common adverse events noted included rash 
(57%), diarrhoea (43%), fatigue (26%) and peripheral oedema (26%). Other 
notable events included reduced ejection fraction/left ventricular dysfunction 
(7%) and one case of chorioretinopthy.41 These appear to be class-effects with 
MEK inhibitors. 
 
 
In terms of the combination of vemurafenib with cobimetinib, a Phase Ib study 
by Ribas et al of vemurafenib/cobimetinib saw 129 patients treated with ten 
different dosing regimens of the combination, in pursuit of the maximum 
tolerated dose (MTD).28 This was established as vemurafenib 960mg twice daily 
continuously and cobimetinib 60mg daily for 3 out of every 4 weeks – ie using 
the maximal single-agent tolerated doses. The study included two populations: 
66 patients who had recently progressed on vemurafenib and 63 who were naïve 
 to both compounds. In all dosing regimens the most common adverse events 
were diarrhoea (64%), non-acneiform rash (60%), liver enzyme abnormalities 
(50%), fatigue (48%), nausea (45%), and photosensitivity (40%). Most events 
were of mild-moderate severity. The most common grade 3 or grade 4 events 
included cutaneous squamous cell carcinoma (9%), raised alkaline phosphatase 
(9%) and anaemia (7%). The combination naïve group had more adverse events 
than those previously treated with vemurafenib, likely reflecting a reporting 
bias. 
 
 
 
In the Phase III coBRIM trial of vemurafenib/cobimetinib compared with 
vemurafenib/placebo, the overall rates of adverse events were similar in both 
arms for all grades of toxicity.32 The most common adverse events seen with 
combination treatment were diarrhoea (56%), nausea (40%), rash (39%), 
arthralgia (32%), fatigue (32%), fever (26%), elevated ALT and AST (24 and 
22% respectively) and vomiting (21%). The patients receiving vemurafenib 
alone had fewer events of diarrhoea (28% vs 56%), nausea (24% vs 40%) and 
vomiting (13% vs 21%), but a higher rate of cutaneous squamous cell carcinoma 
(11% vs 3%), hyperkeratosis (29% vs 10%) and arthralgia (40% vs 32%). Grade 
3 adverse events occurred in 49% in both arms. The majority of Grade 3 events 
seen in the combination arm were abnormal blood results with raised creatine 
kinase (CK; 7%), raised ALT (11%) and AST (8%), as well as diarrhoea (6%), 
rash (5%), and fatigue (4%). In the vemurafenib monotherapy group the most 
common grade 3 events were cutaneous SCCs (11%), raised ALT (6%), rash 
(5%) and arthralgia (5%). Eight percent of subjects suffered a reduced ejection 
fraction, Grade 3 in 1%, and 4% developed a prolonged QT interval, Grade 3 in 
 1%. The incidence of toxic events requiring drug withdrawal was similar in both 
groups (12% in the monotherapy and 13% in the combination group). 
 
 
 
The rate of serous retinopathy is greater with vemurafenib/cobimetinib than 
vemurafenib alone, with 26% versus 3% of patients impacted in the coBRIM 
trial.42 The majority of events were grade 1 or 2 (88%) and mostly picked up on 
routine surveillance. In the few cases where drug therapy was interrupted or 
reduced, 75% resolved or were resolving at the time of reporting. Median time 
to onset was early in treatment at 1 month. 
 
 
 
In the coBRIM trial, 9 patients died from treatment-related causes: 3 in the 
vemurafenib arm (1%) and 6 (2%) in the combination arm. With such small 
numbers, one cannot determine whether this difference is significant. The causes 
of death ranged from general disorders including fatigue to cardiac events. Two 
neurological events occurred in the combination group: cerebral haemorrhage 
and hemiparesis.32 
 
 
In a Phase III trial of the alternative BRAF and MEK inhibitors dabrafenib and 
trametinib in combination compared with dabrafenib alone, the overall adverse 
event rates were very similar. Notable differences included higher rates of fever 
with the combination (52% vs 25%) but fewer episodes of hyperkeratosis (6% 
vs 33%), cutaneous squamous cell carcinoma (3% vs 9%) and alopecia (5% vs 
26%) than seen in the dabrafenib monotherapy arm.9 Comparing across studies 
of vemurafenib/cobimetinib and dabrafenib/trametinib, fever is seen more 
commonly with dabrafenib/trametinib (52% vs 26%), whereas diarrhoea (56% 
 vs 18%), rash (39% vs 24%), nausea (40% vs 20%) arthralgia (32% vs 16%) 
and hyperkeratosis (10% vs 6%) are more common with the combination of 
vemurafenib/cobimetinib. Hyperkeratosis and squamous cell carcinomas 
occurred much less commonly in the combination BRAF/MEK inhibitor groups 
of both Phase III trials relative to BRAF inhibitor monotherapy.8, 32 
 
 
Table 3 outlines adverse events of vemurafenib and cobimetinib compared with 
vemurafenib monotherapy and the combination of its competitor dabrafenib and 
trametinib. 
 
 
5. Regulatory affairs 
 
Vemurafenib is licensed in the United States (US), Europe and Australia for use 
as monotherapy. Cobimetinib is also now licensed for use in combination with 
vemurafenib in the United States (for BRAF V600E and V600K mutations) and 
in Europe (for BRAF V600 mutations) for advanced melanoma, but is not yet 
licensed in Australia. 
 
 
6.1 Conclusion 
 
The combination of vemurafenib with cobimetinib is a highly effective treatment 
option for patients with advanced BRAF mutant melanoma. The addition of 
cobimetinib results in improved response rates as well as significantly longer 
progression-free and overall survival. Availability of this combination provides 
an alternative to the combination of dabrafenib with trametinib, with the 
schedule and toxicity profile differing between the two combinations. The Drug 
Summary Box provides an overview of this combination. 
  
6.2 Expert opinion 
 
The combination of vemurafenib with cobimetinib provides an alternative to 
dabrafenib and trametinib in patients with advanced BRAF mutant melanoma. 
Our practice is to reserve these combinations for use in patients with a critical 
burden of disease, or brain-predominant disease, given their high objective 
response rates (around 70%)8, 32 and the efficacy of BRAF monotherapy in the 
treatment of central nervous system lesions43, 44, from which we extrapolate 
that the combination will be at least as effective. Use of 
vemurafenib/cobimetinib upfront, as opposed to addition of cobimetinib later, 
is the most appropriate way to initiate this therapeutic combination. 
 
 
 
Though similar in efficacy, the adverse event profile of vemurafenib/cobimetinib 
differs from dabrafenib/trametinib in a number of areas. Febrile episodes are 
less common. On the other hand, its more complex, intermittent dosing schedule 
and greater number of tablets (due to relatively less bioavailability than 
dabrafenib/trametinib) may make it less preferable to some. The 
photosensitivity associated mainly with vemurafenib can be problematic for 
anyone regularly exposed to sunlight and the higher rates of diarrhoea, rash, 
nausea and arthralgias may have a significant impact on quality of life. The 
availability of this combination is unlikely to change current drug-treatment 
strategies, however marketplace competition may increase availability of 
BRAF/MEK combination therapies as less exclusivity could reduce the price. The 
outcome of the Phase III trial with encorafenib and binimetinib (NCT01909453) 
may see a third combination become available. 
 
 
 
Physicians should feel comfortable in prescribing this combination, but need to 
counsel patients appropriately regarding expected side effects. Out practice is to 
recommend high SPF-factor sunscreen and avoidance of direct sunlight to 
prevent photosensitivity, as well as to prescribe prophylactic anti-emetics and 
anti-diarrhoeal medication. Although the addition of cobimetinib to vemurafenib 
elevates risk of cardiac dysfunction and ocular toxicity, we do not routinely 
undertake echocardiograms and ophthalmology review. High risk patients, or 
those who develop symptoms suggestive of one of these rare side effects, should 
have a prompt clinical assessment. There is also potential for radiation recall and 
sensitization when vemurafenib and radiotherapy are combined. The skin is 
particularly vulnerable but other organs may be impacted. In November 2015 
the UK government issued a specific warning to this effect.45 
 
 
The careful development of vemurafenib provides an example of how an active 
agent may be potentiated to allow greater specificity for a target, resulting in 
both superior clinical efficacy and tolerability.21 The ORR of 80% in the Phase I 
trial is testament to this.28 The concept of dual MAPK protein blockade to defer 
resistance may be further exploited as technology enables us to design effective 
RAS and ERK inhibitors. Patients may change their co-inhibitor at -or ideally just 
prior to- clinical progression, based on the mechanism of developed resistance. 
In terms of alternative scheduling, there is preclinical evidence supporting 
evaluation of an intermittent dosing approach. Research in mice has shown that 
vemurafenib-resistant melanomas become drug-dependent for their 
proliferation and may regress upon drug cessation.46 
 
 
 
Although the original study looking at combination vemurafenib with 
ipilimumab, an anti-CTLA4 antibody, resulted in significant hepatotoxicity47, the 
potential for synergy remains and ongoing trials are in progress, as discussed 
above. Our understanding of the way in which BRAF inhibition and therapeutic 
resistance may alter the tumour microenvironment is expanding.48 Trials such 
as SECOMBIT (NCT02631447) will enable further insight into the best way of 
sequencing BRAF/MEK inhibition with immune checkpoint blockade. 
 
 
 
Finally, use of vemurafenib/cobimetinib may not be limited to use in advanced 
melanoma patients in future. As already discussed in the Clinical Efficacy 
section, use in the neoadjuvant setting may improve both surgical and disease 
outcomes and we await results from ongoing trials to elucidate this. 
 
 
Drug summary box  
Drug names (generic) Vemurafenib and cobimetinib 
  
Phase Licensed in the US and Europe 
  
Indication (specific to Advanced melanoma with a BRAF V600 mutation (ie 
discussion) unresectable Stage III or Stage IV disease). 
 
Both agents are tyrosine kinase inhibitors targeting 
MAPK pathway proteins. Vemurafenib selectively  
inhibits the mutant BRAF protein where cobimetinib 
Pharmacology and mechanism binds to MEK in its activated, phosphorylated form. This  
of action results in reduced oncogenic signally, tumour cell cycle arrest and apoptosis 
and translates into improved clinical outcomes. 
 
 
Route of administration Both are administered orally in tablet form. 
 
co-BRIM study32: International, randomised, blinded 
placebo-controlled trial evaluating the benefit of  
Pivotal trial combination vemurafenib/cobimetinib over vemurafenib/placebo. This 
trial demonstrated improved response rates and 
survival with combination 
 
therapy. 
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Table 1: Pharmacokinetics of vemurafenib and cobimetinib  
 Vemurafenib49 Cobimetinib50, 51 
   
Oral bioavailability High inter-patient 45.9%; not impacted by 
 variability; improved with food intake 
 high-fat meal; high  
 accumulation at steady  
 state  
Half-life 51.6 hours (5th-95th 43.6 hours (range 23.1- 
 percentile range 29.8- 69.6) 
 115.5)  
   
Volume distribution 91L (64.8% between 806L; 94.8% protein-bound 
 patient variability); in vitro in vitro 
 >99% protein-bound  
Metabolism CYP3A4 identified as main CYP3A oxidation and 
 mechanism in vitro, glucuronidation by UGT2B7 
 glucuronidation and  
 glycosylation contribute in  
 vivo  
Clearance 29.3L/hour; eliminated in 13.8L/hour; eliminated in 
 faeces (94%) and urine faeces 
 (1%); probable additional  
 biliary excretion; renal and  
 hepatic excretion unknown  
Table 2: Summary of efficacy results from Phase I and III trials of 
vemurafenib with cobimetinib, as well as Phase III results of 
dabrafenib with trametinib 
Trial Phase Drugs Number Median Overall Complete Median 1 
 tested patients PFS response response OS year 
   (months) rate rate (months) OS 
Phase 1b28 Vem+Cobi 63 13.7 87% 10% Not 83% 
 BRAFi     reached  
 naïve       
        
 Vem+Cobi 66 2.8 15% 0% 8.3 32% 
 previous       
 BRAFi       
        
Phase 3 Vem+Cobi 248 12.3 70% 16% 22.3 75% 
(coBRIM)33,        
34 Vem+Plac 247 7.2 50% 11% 17.4 nd 
 
        
Phase 3 Dab+Tram 211 11.0 69 16 25.1 74% 
(Combi-D)8 Dab 212 8.8 53 13 18.7 68% 
Phase 3 Dab+Tram 352 11.4 64 13 Not 72% 
(Combi-v)10      reached  
 Vem 352 7.3 51 8 17.2 65% 
 
Vem+Cobi= vemurafenib and cobimetinib; Vem+Plac= vemurafenib and placebo; 
Dab+Tram=dabrafenib and trametinib; PFS= progression free survival; OS= overall 
survival 
Table 3: Adverse event rates with vemurafenib and Cobimetinib compared 
to vemurafenib monotherapy and the combination of dabrafenib with 
trametinib 
Adverse Events Vemurafenib/ Vemurafenib32 Dabrafenib/ 
 Cobimetinib32   Trametinib8 
       
 All G3/G4 All G3/G4 All G3* 
 (%) (%) (%) (%) (%) (%) 
       
Any Adverse 95 49/13 96 49/9 87 32 
Event       
Systemic       
Fever 26 2/0 22 0/0 52 7 
       
Fatigue 32 4/0 31 3/0 27 2 
       
Gastrointestinal       
Diarrhoea 56 6/0 28 0/0 18 <1 
       
Nausea 40 1/0 24 1/0 20 0 
       
Vomiting 21 1/0 13 1/0 14 <1 
       
Skin       
Rash-General 39 5/1 35 5/0 24 0 
       
Hyperkeratosis 10 0/0 29 2/0 6 0 
       
Cutaneous SCCs 3 2/0 11 11/0 3 3 
       
Musculolskeletal       
Arthralgia 32 2/0 40 5/0 16 <1 
       
Cardiac       
Reduced Ejection 8 1/0 3 1/0 4 1 
Fraction       
QT prolongation 4 1/0 4 1/0 nd nd 
       
Ophthalmic       
Retinal 8 2/<1 0 0/0 nd nd 
Detachment       
Laboratory Abnormalities      
Increased 31 7/4 <4 1/0 nd nd 
Creatine Kinase       
Increased ALT 24 11/<1 19 6/<1 10 2 
       
Increased AST 22 8/0 13 2/<1 11 3 
        
n/d = not documented. 
*G4 not reported 
Figure 1: Oncogenic signaling via the MAPK pathway 
